Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder with progressive extraskeletal endochondral bone formation; classic FOP patients have congenital malformation of the great toes and develop heterotopic ossification in soft tissues via an endochondral pathway (cartilage forms first, then is replaced by bone).
The classic FOP mutation is a recurrent missense change in ACVR1/ALK2, a BMP type I receptor: c.617G→A, resulting in R206H in the GS (glycine/serine-rich) activation domain of ACVR1. ACVR1 is expressed in cartilage and skeletal muscle, aligning with skeletal malformations and sites of heterotopic ossification.
BMP signaling is essential for bone and cartilage formation and development; BMPs bind type I and II receptors to activate downstream Smad signaling (R-Smads Smad1/5/8 with Smad4). FKBP1A (FKBP12) binds GS domains of type I receptors to inhibit ligand-independent activation in the absence of BMP and prevents leaky activation.
Zebrafish Alk8 is the functional ortholog of ACVR1/ALK2 and mediates BMP2/4/7 signaling upstream of Smad5; loss-of-function laf mutants dorsalize due to reduced BMP signaling, whereas BMP pathway activation ventralizes.
This study tests whether the FOP R206H ACVR1 mutation activates BMP signaling without BMP ligand and whether it can induce BMP-independent chondrogenesis, using in vitro mammalian cell lines, chick micromass cultures, and zebrafish embryo models.
Key findings
The R206H ACVR1 mutant activates BMP signaling in the absence of BMP ligand and also enhances BMP signaling when ligand is present (BMP-responsive).
The mutant shows reduced binding to FKBP1A in the absence of BMP, suggesting a mechanism for BMP-independent receptor activation via GS-domain misregulation.
In zebrafish embryos, R206H ACVR1 causes BMP-independent hyperactivation of BMP signaling, leading to ventralization during development; this requires Smad signaling (Smad5 in particular).
In vivo and in vitro analyses indicate that the mutant receptor can promote chondrogenesis even without BMP ligand, and that Noggin (a BMP antagonist) can dampen this activity in the mutant context, illustrating partial BMP independence with BMP responsiveness.
The mutant exerts a milder, more gradual chondrogenic effect than a constitutively active ACVR1 (caACVR1 Q207D), yet still engages the Smad pathway and endochondral differentiation.
The data imply that R206H ACVR1 acts downstream of ligand and can be BMP-independent while still being subject to BMP modulation, which has implications for modeling FOP and developing therapeutic strategies.
Results
R206H ACVR1 activates BMP-independent signaling and remains BMP-responsive
Experimental setup: COS-7, C2C12, and U-2 OS cells transfected with wild-type ACVR1 or R206H ACVR1, plus an ID1 promoter luciferase reporter (–985/+94).
Observation: In COS-7 cells, ID1 promoter activity increased by 3.0±0.2-fold in R206H vs WT ACVR1 without BMP; similar results in C2C12 and U-2 OS cells (Figure 1A).
BMP treatment increased ID1 promoter activity for both WT and R206H, but the relative fold differences between mutant and WT were not significantly different in these assays (data not shown).
Immunoblot analysis showed that R206H ACVR1 induced phosphorylation of Smad1/5/8 in the absence of exogenous BMP, whereas WT ACVR1 did not (Figure 1B); this was observed in COS-7 and MC3T3-E1 cells. No change in Smad2 phosphorylation was detected, indicating specificity for BMP signaling.
In p38 MAPK assays, R206H ACVR1 did not increase p38 phosphorylation, suggesting the BMP-independent activation largely uses the Smad pathway rather than the p38 axis.
Conclusion: R206H ACVR1 activates BMP signaling without ligand and can still respond to BMP when present, engaging canonical Smad signaling pathways.
Mutant ACVR1 shows impaired FKBP1A binding in the absence of BMP
R206H ACVR1 binds FKBP1A less effectively than WT ACVR1 in COS-7 cells lacking BMP (Figure 2A).
Upon BMP treatment, WT ACVR1 reduces FKBP1A association as expected; R206H ACVR1 shows little change in FKBP1A binding after BMP exposure (Figure 2A).
Reciprocal IPs (ACVR1 pull-down and FKBP1A blots) confirmed reduced mutant-FKBP1A interaction relative to WT in the absence of BMP (Figure 2B).
Interpretation: Impaired GS-domain interaction with FKBP1A in the R206H mutant could permit leaky receptor activation and BMP signaling without ligand.
The R206H ACVR1 mutant causes BMP-independent hyperactivation of signaling in zebrafish embryos
Zebrafish model: Alk8 (ACVR1 ortholog) controls DV patterning. laf mutants lack Alk8 signaling and dorsalize the embryo; wild-type human ACVR1 can rescue Alk8 deficiency.
Experiment: Wild-type ACVR1 or R206H ACVR1 mRNA injected into alk8–/– embryos; analyze ventralization and marker expression.
Results: WT ACVR1 rescued ~80% of embryos; R206H ACVR1 caused strong ventralization in alk8–/– embryos (Figures 3D–F), with head and tail defects indicating gastrulation-stage disruption.
Marker analysis: Eve1 and gata2 ventral marker expansion and foxb1 (dorsal marker) restriction during gastrulation in R206H-injected embryos (Figure 3, G–L).
Conclusion: R206H ACVR1 drives BMP signaling in vivo in a BMP-independent manner, promoting ventralization via Smad signaling.
BMP signaling and Smad dependence in vivo
To test Smad requirement, Smad5 translation was blocked with morpholinos in wild-type embryos; this dorsalized the embryos (C4/C5 phenotypes).
When Smad5 MO was co-injected with mutant R206H ACVR1, ventralization was blocked, indicating Smad5 is required downstream of R206H ACVR1 for ventralization (Figure 4, E–H).
Dorsomorphin (DM), a BMP type I receptor inhibitor that blocks Smad signaling, completely blocked R206H ACVR1–induced ventralization (Figure 4I).
BMP ligands bmp2b and bmp7: loss of either ligand or both (via bmp2b or bmp7 single/double mutants or morpholino knockdown) results in dorsalization, but R206H ACVR1 can still induce ventralization in BMP-ligand–deficient embryos, signaling that R206H ACVR1 acts downstream of BMP ligand and can activate BMP signaling in a BMP-independent manner (Figure 5).
Conclusion: R206H ACVR1–mediated ventralization depends on Smad signaling and can function independently of BMP ligands, consistent with BMP-independent but Smad-mediated activation.
Mutant R206H ACVR1 enhances chondrogenesis in BMP-independent and BMP-responsive contexts
Chick limb bud micromass cultures used to assess chondrogenesis via retroviral infection with RCASBP(A) carrying either WT ACVR1, R206H ACVR1, or caACVR1 Q207D, with or without Noggin (NOG) coexpression (Noggin blocks BMP ligands).
Alcian blue staining (glycosaminoglycan matrix) after 7 days showed no effect with WT ACVR1; R206H ACVR1 produced a steady increase in matrix accumulation; caACVR1 Q207D produced a stronger effect (Figure 6A).
Quantification of Alcian blue by dye extraction confirmed differences among groups (Figure 6B).
ALP staining (prehypertrophic marker) after 9 days indicated differentiation progress: caACVR1 Q207D produced a robust ALP signal; R206H ACVR1 induced a milder increase; Noggin coexpression reduced differentiation in WT ACVR1 but had a reduced effect on mutants (Figure 6C–D).
Gene expression: qRT-PCR for chondrogenesis markers showed R206H ACVR1 modestly upregulates early chondrogenesis markers (Col II, Aggrecan) compared with WT; caACVR1 Q207D upregulates later-stage markers (Ihh, Col X) and downregulates Col II notably; Noggin coexpression dampens marker expression in WT but not fully in R206H or caACVR1 contexts (Figure 6E).
Interpretation: R206H ACVR1 can enhance chondrogenic differentiation, partially BMP-independent but still BMP-responsive, with a milder effect than caACVR1 Q207D. Noggin reduces the effect but does not abolish it in the mutant context.
Molecular markers and signaling implications
In the micromass system, early chondrogenesis markers (Col II, Aggrecan) respond to R206H but not with the same magnitude as caACVR1 Q207D; later markers Ihh and Col X show greater changes with caACVR1 than with R206H, consistent with a milder stimulatory profile for R206H ACVR1.
Noggin dramatically suppresses chondrogenic markers in WT ACVR1 cultures, but has a lesser effect on R206H ACVR1 and caACVR1, indicating that the mutant receptor can bypass some BMP ligand requirements while remaining partly BMP-responsive.
Overall, R206H ACVR1 induces a constitutive, BMP-independent push toward chondrogenesis that can be further modulated by BMP ligands.
Discussion
The R206H ACVR1 mutation is activating and leads to BMP signaling without ligand, with additional BMP responsiveness. This dual nature aligns with the ectopic endochondral bone formation in FOP and explains how tissue environments could trigger episodes of heterotopic ossification.
Mechanistically, the mutation likely alters the GS domain conformation or phosphorylation, reducing FKBP1A binding and enabling leaky receptor activation in the absence of ligand. However, FKBP1A binding is not completely abolished, suggesting a nuanced, partial disruption that still allows some regulation.
The in vivo zebrafish data show that BMP signaling is robustly activated by R206H ACVR1 in developing embryos, but the phenotype is Smad-dependent, reinforcing the canonical BMP–Smad pathway as the primary mediator of this effect.
The phenotype differences between R206H ACVR1 and caACVR1 Q207D imply that R206H is a milder activating mutation. This could explain why FOP patients have relatively mild embryonic skeletal malformations but develop severe heterotopic ossification later in life.
The authors discuss the possibility that the mutant receptor is only moderately activating under basal conditions, allowing quiescent periods between active episodes of HO, but priming cells to respond to local tissue cues.
The study highlights the translational potential: understanding R206H ACVR1 signaling can inform models to test pharmacologic inhibitors that block this receptor’s aberrant activity.
Limitations include the use of transient transfection systems and non-mutant gene dosage that may not perfectly mirror heterozygous patient cells. A knock-in ACVR1 R206H mouse model is proposed to better mimic gene dose effects and disease biology.
In conclusion, ACVR1 R206H in FOP acts as an activating mutation that enhances chondrogenesis and BMP signaling in a BMP-independent yet BMP-responsive manner, providing a mechanistic basis for ectopic endochondral ossification and guiding future therapeutic strategies.
Methods (summary and key points)
Plasmids and constructs
Human ACVR1 WT and R206H cDNA constructs in pcDNA3.1 with a C-terminal V5 tag; the R206H mutation introduced by site-directed mutagenesis at cDNA position 617 (G→A).
For chick micromass studies, ACVR1 variants cloned into RCASBP(A) (avian retroviral) and Noggin into RCASBP(B).
Cell culture and transfection
Cells: COS-7, C2C12, MC3T3-E1, U-2 OS; culture in DMEM, α-MEM, or McCoy’s 5A with 10% FBS.
Transfection: FuGene 6; luciferase assays normalized to Renilla via pRL-TK; efficiency ~60–70% as measured with GFP co-transfection.
Immunoblot and immunoprecipitation
Antibodies: anti-phospho-Smad1/5/8, anti-Smad1, anti-V5, anti-β-actin; standard Western blot protocols.
Immunoprecipitations to assess ACVR1–FKBP1A interactions, with and without BMP treatment (BMP4 or BMP7).
Micromass culture and chondrogenesis assays
Chick limb bud mesenchymal cells infected with RCASBP(A) carrying WT or mutant ACVR1, +/- Noggin; Alcian blue staining for proteoglycan matrix; ALP staining for prehypertrophic differentiation.
Quantification: dye extraction for Alcian blue; histomorphometric ALP analysis.
Gene expression: qRT-PCR for Col II, Col X, Ihh, Aggrecan, using 28S rRNA as a housekeeper; normalization with qBase software.
Zebrafish experiments
Zebrafish strains: Alk8/Lost-a-fin (laf) background; BMP ligands bmp2b and bmp7 used as dorsal-ventral axis determinants.
mRNA injections: WT ACVR1 or R206H ACVR1 into embryos; dose ranges included 6–60 pg for rescue experiments, 10 pg for ventralization, and higher doses for robust phenotypes.
Morpholino knockdowns: smad5 MO1 and MO3; bmp2b MO; control injections.
Treatment with dorsomorphin (DM) at 40 μM to inhibit BMP signaling.
In situ hybridization for ventral (eve1, gata2) and dorsal (foxb1.2) markers; Western blot for phospho-Smad1/5 in embryo extracts.
Data analysis and statistics
Means ± SEM; significance typically assessed by t-tests with P < 0.05 considered significant.
Figures and what they show (textual references)
Figure 1: R206H ACVR1 increases ID1 transcription and induces Smad1/5/8 phosphorylation without BMP; WTACVR1 does not; both receptors respond to BMP when present.
Figure 2: Reduced FKBP1A binding to R206H ACVR1 compared to WT in the absence of BMP; BMP treatment restores WT binding but not mutant binding changes substantially.
Figure 3: In zebrafish alk8–/– embryos, WT ACVR1 rescues DV patterning, while R206H ACVR1 causes ventralization; ventral markers expanded, dorsal marker suppressed; increased p-Smad1/5 with R206H.
Figure 5: BMP ligand deficiency (bmp2b/bmp7 mutants) does not prevent R206H ACVR1–induced ventralization; mutant acts downstream of ligands.
Figure 6: In chick micromass, R206H ACVR1 enhances chondrogenesis (Alcian blue, ALP); Noggin dampens WT ACVR1 activity but not fully the R206H mutant; caACVR1 Q207D shows stronger differentiation. Gene expression patterns reflect stages of chondrogenesis and BMP responsiveness.
Real-world relevance and implications
The findings provide a mechanistic link between the ACVR1 R206H mutation and ectopic endochondral ossification in FOP, clarifying how a receptor activating mutation can drive BMP signaling without ligand yet still respond to BMP cues.
These insights support targeting the BMP/Smad pathway for therapeutic strategies and highlight the potential for BMP pathway inhibitors (e.g., dorsomorphin-like compounds) to mitigate aberrant signaling in FOP.
The partial BMP independence of R206H ACVR1 suggests a need for therapies that both dampen constitutive activity and modulate pathway responsiveness to BMP ligands, possibly reducing flare-ups while preserving normal BMP functions during development.
Connections to foundational principles and prior work
The study ties into the broader framework of TGF-β/BMP signaling: ligand binding activates type I receptors, which, with type II receptors, phosphorylate the GS domain and downstream Smads to regulate transcription of targets like Id1.
FKBP1A’s role as a negative regulator of BMP receptor activation is reinforced; mutations that weaken FKBP1A binding can cause ligand-independent signaling.
The zebrafish DV patterning model provides a robust in vivo system to study BMP signaling dynamics and receptor function, linking molecular signaling to macroscopic embryonic patterning.
Ethical, philosophical, and practical implications
Ethically, animal models (zebrafish) are used to model a human disease; care is needed to ensure humane treatment and justify the translational benefit.
Practically, understanding BMP-independent activation informs drug development strategies that aim to prevent ectopic bone formation in FOP without compromising normal BMP signaling essential for development and homeostasis.
Philosophically, the work illustrates how a single-point mutation in a signaling receptor can rewire pathway regulation, emphasizing the delicate balance of signaling networks in development and disease.
Equations and numerical references (LaTeX)
ID1 promoter activity fold change in R206H vs WT ACVR1 (BMP-free): extID1activityextR206H=3.0±0.2-fold over WT.
BMP signaling readouts include phosphorylated Smad1/5/8; no explicit numerical values beyond qualitative increases are provided in the text, but increases are shown by immunoblotting (Figure 1B) and are consistent across COS-7 and MC3T3-E1 cells.
BMP ligand doses used in zebrafish injections: 6 pg,10 pg,50 pg,60 pg ranges for ACVR1 mRNA; DM treatment at 40μM.
Morpholino dosages: smad5 MO1 and MO3 amounts; bmp2b MO amount (1 ng per embryo).
Statistical significance: P<0.05 used for determining significance in multiple comparisons; data represented as mean ± SEM.
Summary takeaways
The ACVR1 R206H mutation in FOP activates BMP signaling without ligand and also remains responsive to BMP, leading to enhanced chondrogenesis and ventralization in vivo.
The mechanism involves reduced FKBP1A binding to the GS domain, enabling leaky receptor activation; Smad signaling is required for the in vivo effects, as shown by Smad5 knockdown and DM inhibition.
The mutant can function downstream of BMP ligands, as evidenced by ventralization in BMP-deficient contexts, yet still exhibits BMP-responsive features, aligning with the complex dysregulation seen in FOP.
These findings support the pursuit of therapeutic agents that can specifically target mutant ACVR1 signaling pathways to prevent heterotopic ossification while preserving normal BMP function.